EUVIMEDEUVIMED entdecken
Crossref

Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway

Hongyu Geng, Hongbo Zhang, Lianfang Cheng, Shimin Dong

International Immunopharmacology · 2024-02 · 128 · 111466

DOI: 10.1016/j.intimp.2023.111466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-02. Verfasst von Hongyu Geng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit, Baoding First Central Hospital, Baoding, China. Hauptthemen laut MEDLINE: Cardiomyopathies, Sepsis, Sulfonamides. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cardioprotective role of sivelestat, a neutrophil elastase inhibitor, has already been demonstrated, but the underlying molecular mechanism remains unclear. This study aimed to explore the mechanism underlying the role of sivelestat in sepsis-induced myocardial dysfunction (SIMD). We found that sivelestat treatment remarkably improved the viability and suppressed the apoptosis of lipopolysaccharide (LPS)-stimulated H9c2 cells. In vivo, sivelestat treatment was associated with an improved survival rate; reduced serum cTnT, TNF-α, IL-1β levels and myocardial TNF-α and IL-1β levels; ameliorated cardiac function and structure; and reduced cardiomyocyte apoptosis. Moreover, sivelestat treatment substantially increased Bcl-2 expression and suppressed caspase-3 and Bax expression in LPS-induced H9c2 cells and in the heart tissues of septic rats. Furthermore, the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) signaling pathway was activated both in vitro and in vivo. The protective effect of sivelestat against SIMD was reversed by the PI3K inhibitor LY294002. In summary, sivelestat can protect against SIMD by activating the PI3K/AKT/mTOR signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesSepsisSulfonamidesRatsAnimalsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesTumor Necrosis Factor-alphaLipopolysaccharidesRats, Sprague-DawleySignal TransductionTOR Serine-Threonine KinasesApoptosisGlycine

Stichwörter der Autor:innen

ApoptosisPI3K/AKT/mTORSepsis-induced myocardial dysfunctionSivelestat

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasessivelestatTumor Necrosis Factor-alphaLipopolysaccharidesTOR Serine-Threonine KinasesmTOR protein, ratGlycineSulfonamides

Autor:innen und Institutionen

  • Department of Intensive Care Unit, Baoding First Central Hospital, Baoding, China.
  • Department of General Surgery, Baoding First Central Hospital, Baoding, China.
  • Department of Emergency, The Third Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address: jzyy18830296336@126.com.

Zitieren

APA

Geng, H., Zhang, H., Cheng, L., & Dong, S. (2024). Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway. International Immunopharmacology, 128, 111466. https://doi.org/10.1016/j.intimp.2023.111466

Vancouver

Geng H, Zhang H, Cheng L, Dong S. Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway. International Immunopharmacology. 2024;128:111466. doi:10.1016/j.intimp.2023.111466

BibTeX
@article{Geng2024,
  author = {Geng, Hongyu and Zhang, Hongbo and Cheng, Lianfang and Dong, Shimin},
  title = {Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {128},
  pages = {111466},
  doi = {10.1016/j.intimp.2023.111466}
}
Kostenlos starten →